Orion Tong
Garvan Institute for Medical Research, Infinitopes Limited, University of Oxford, The University of Sydney, Weatherall Institute of Molecular Medicine
Research areas: Immunology and Microbiology · Immunology · Immunotherapy and Immune Responses · Cancer Immunotherapy and Biomarkers · T-cell and B-cell Immunology
0000-0002-0659-5944
About
2025-: Garvan Institute for Medical Research, R&D Lead
2022-2025: Infinitopes Limited, Chief of Staff & Employee #4 for a CRUK and Oxford University Spinout
2019-2023: University of Oxford, DPhil in Fairfax Lab at the Weatherall Institute for Molecular Medicine
2017-2019: University of Sydney, Research Assistant in Nasr/Cunningham Lab at the Westmead Institute for Medical Research
2014-2017: University of Sydney, BSc. Adv Hons w/ University Medal
Employment
-
Garvan Institute for Medical Research R&D Lead2025 - Present
-
Infinitopes Limited Chief of Staff, Computational Lead2022 - 2025
-
Weatherall Institute of Molecular Medicine DPhil Student, Fairfax Lab2019 - 2023
-
Westmead Institute for Medical Research Research Assistant2017 - 2019
Education
-
University of Oxford PhD Student2019 - 2023
-
University of Sydney Bachelor of Science (Adv) (Hons Class I w/ the University Medal)2014 - 2017
Projects & Funding
Projects & funding information is unavailable.
Publications (26)
- Lymphocyte Stability Following Immune Checkpoint Blockade Is Coupled to Mitochondrial Haplogroup and Clinical Outcome in Advanced Melanoma Save
- Seq-ing the Truth Save
- Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities Save
- Anti-CMV IgG Titre Determines Organ-Specific Protection Towards Immune Checkpoint Blockade Induced Toxicities Save
- Genetic determinants of monocyte splicing are enriched for disease susceptibility loci Save
- Defining the genetic determinants of CD8+ T cell receptor repertoire in the context of immune checkpoint blockade Save
- CMV serostatus is associated with improved survival and delayed toxicity onset following anti-PD-1 checkpoint blockade Save
- Defining the genetic determinants of CD8+T cell receptor repertoire in the context of immune checkpoint blockade Save
- Genetic determinants of monocyte splicing are enriched for disease susceptibility loci including for COVID-19 Save
- Severe acute myositis and myocarditis on initiation of 6-weekly pembrolizumab post-COVID-19 mRNA vaccination. Save
- Characterization of the genetic determinants of context-specific DNA methylation in primary monocytes. Save
- Peripheral monocyte transcriptomics associated with immune checkpoint blockade outcomes in metastatic melanoma Save
- Deep sequencing of the T cell Receptor reveals common and reproducible CD8+signatures of response to checkpoint immunotherapy Save
- IFNγ signaling in cytotoxic T cells restricts anti-tumor responses by inhibiting the maintenance and diversity of intra-tumoral stem-like T cells Save
- IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma Save
- Natural Killer cells demonstrate distinct eQTL and transcriptome-wide disease associations, highlighting their role in autoimmunity Save
- The HIV-1 proviral landscape reveals that Nef contributes to HIV-1 persistence in effector memory CD4+ T cells Save
- A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Save
- An immunodominant NP105-113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Save
- Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 + T cell clone size and cytotoxicity Save